26 Jul Prescient Therapeutics
Steven Yatomi-Clarke, CEO
Oct. 12 | 11:20am | Oxford Biomedica Ballroom
Melbourne, Australia
(ASX: PTX)
In-person Presentation
Prescient Therapeutics has two novel cell therapy platform technologies. OmniCAR is a universal immune receptor platform enabling controllable T cell activity and multi-antigen targeting with a single cell product. OmniCAR is based on technologies licensed from UPenn and Oxford. OmniCAR provides a method for single-vector, single cell product targeting multiple antigens simultaneously or sequentially, whilst allowing post infusion control and sustained T cell response. CellPryme-M is a minimal intervention manufacturing enhancement that produces more favorable cell phenotype, including 50% more memory T cells; doubling helper T cells and significantly greater chemokine receptor expression for greater tumor trafficking and penetrance. CellPryme-M doubled the performance of CAR T in tumor control and survival in immunocompetent mouse models with aggressive and resistant breast cancer. Cell therapies that could benefit from additional productivity in manufacturing or increased potency and durability in-vivo would be good candidates for CellPryme.
